Literature DB >> 15377059

Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.

Hugh D Riordan1, Neil H Riordan, James A Jackson, Joseph J Casciari, Ron Hunninghake, Michael J González, Edna M Mora, Jorge R Miranda-Massari, Norberto Rosario, Alfredo Rivera.   

Abstract

A series of seven cases are presented in which intravenous vitamin C has been used as antineoplastic agent in the treatment of different types of cancers. The cancers cases reviewed are the following: Renal cell carcinoma (2), Colorectal cancer (1), Pancreatic cancer (1), Non-Hodgkin's lymphoma (2) and breast cancer (1). Toxic reactions were not observed at these high doses of intravenous Vitamin C. All patients were prescreened for Glucose 6--phosphate dehydrogenase deficiency before administering intravenous Vitamin C in order to prevent hemolysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377059

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  23 in total

Review 1.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

2.  Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis.

Authors:  Michael J Gonzalez; Jorge R Miranda Massari; Jorge Duconge; Neil H Riordan; Thomas Ichim
Journal:  J Orthomol Med       Date:  2012-01-01

3.  Intravenously administered vitamin C as cancer therapy: three cases.

Authors:  Sebastian J Padayatty; Hugh D Riordan; Stephen M Hewitt; Arie Katz; L John Hoffer; Mark Levine
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

Review 4.  Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.

Authors:  Nermi L Parrow; Jonathan A Leshin; Mark Levine
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

Review 5.  Treatment of Pancreatic Cancer with Pharmacological Ascorbate.

Authors:  John A Cieslak; Joseph J Cullen
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

Review 6.  Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.

Authors:  Carmel Jacobs; Brian Hutton; Terry Ng; Risa Shorr; Mark Clemons
Journal:  Oncologist       Date:  2015-01-19

7.  Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro.

Authors:  Giovanni Vanni Frajese; Monica Benvenuto; Massimo Fantini; Elena Ambrosin; Pamela Sacchetti; Laura Masuelli; Maria Gabriella Giganti; Andrea Modesti; Roberto Bei
Journal:  Oncol Lett       Date:  2016-04-27       Impact factor: 2.967

Review 8.  Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy.

Authors:  M S Petronek; J M Stolwijk; S D Murray; E J Steinbach; Y Zakharia; G R Buettner; D R Spitz; B G Allen
Journal:  Redox Biol       Date:  2021-01-16       Impact factor: 10.787

9.  Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

Authors:  Christopher M Stephenson; Robert D Levin; Thomas Spector; Christopher G Lis
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-14       Impact factor: 3.333

10.  Anti-angiogenic effect of high doses of ascorbic acid.

Authors:  Nina A Mikirova; Thomas E Ichim; Neil H Riordan
Journal:  J Transl Med       Date:  2008-09-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.